• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定鞘氨醇激酶1(SphK1)为淫羊藿素在肝癌细胞中的主要靶点。

Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells.

作者信息

Lu Pei-Hua, Chen Min-Bin, Liu Yuan-Yuan, Wu Mian-Hua, Li Wen-Ting, Wei Mu-Xin, Liu Chao-Ying, Qin Shu-Kui

机构信息

Department of Medical Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China.

Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor of Nanjing University of Chinese Medicine, Nanjing, China.

出版信息

Oncotarget. 2017 Apr 4;8(14):22800-22810. doi: 10.18632/oncotarget.15205.

DOI:10.18632/oncotarget.15205
PMID:28206952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5410263/
Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive neoplasm. We aim to explore the anti-HCC activity by a natural prenylflavonoid icaritin. Icaritin was cytotoxic and pro-apoptotic when added to established (HepG2, KYN-2 and Huh-7 lines) and primary human HCC cells. At the signaling level, icaritin inhibited sphingosine kinase 1 (SphK1) activity in HCC cells, which led to pro-apoptotic ceramide production and JNK1 activation. SphK1 inhibition or silence (by shRNA/microRNA) mimicked icaritin-mediated cytotoxicity, and almost nullified icaritin's activity in HepG2 cells. Reversely, exogenous over-expression of SphK1 sensitized icaritin-induced HepG2 cell apoptosis. In vivo, oral administration of icaritin dramatically inhibited HepG2 xenograft growth in SCID mice. Further, SphK1 activity in icaritin-treated tumors was largely inhibited. In summary, icaritin exerts potent anti-HCC activity in vitro and in vivo. SphK1 inhibition could be the primary mechanism of its actions in HCC cells.

摘要

肝细胞癌(HCC)是一种侵袭性很强的肿瘤。我们旨在探索天然异戊烯基黄酮类化合物淫羊藿素的抗HCC活性。当将淫羊藿素添加到已建立的(HepG2、KYN-2和Huh-7细胞系)及原代人HCC细胞中时,它具有细胞毒性并能促进细胞凋亡。在信号传导水平上,淫羊藿素抑制HCC细胞中的鞘氨醇激酶1(SphK1)活性,这导致促凋亡的神经酰胺生成和JNK1激活。SphK1抑制或沉默(通过短发夹RNA/微小RNA)模拟了淫羊藿素介导的细胞毒性,并且几乎消除了淫羊藿素在HepG2细胞中的活性。相反,SphK1的外源性过表达使淫羊藿素诱导的HepG2细胞凋亡更加敏感。在体内,口服淫羊藿素显著抑制了SCID小鼠中HepG2异种移植瘤的生长。此外,淫羊藿素处理的肿瘤中的SphK1活性被很大程度地抑制。总之,淫羊藿素在体外和体内均发挥强大的抗HCC活性。SphK1抑制可能是其在HCC细胞中发挥作用的主要机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f08/5410263/bfff58d6db4f/oncotarget-08-22800-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f08/5410263/dba8652959db/oncotarget-08-22800-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f08/5410263/9ca614480de7/oncotarget-08-22800-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f08/5410263/4eb0549ed65f/oncotarget-08-22800-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f08/5410263/934024ca36f8/oncotarget-08-22800-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f08/5410263/bfff58d6db4f/oncotarget-08-22800-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f08/5410263/dba8652959db/oncotarget-08-22800-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f08/5410263/9ca614480de7/oncotarget-08-22800-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f08/5410263/4eb0549ed65f/oncotarget-08-22800-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f08/5410263/934024ca36f8/oncotarget-08-22800-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f08/5410263/bfff58d6db4f/oncotarget-08-22800-g005.jpg

相似文献

1
Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells.鉴定鞘氨醇激酶1(SphK1)为淫羊藿素在肝癌细胞中的主要靶点。
Oncotarget. 2017 Apr 4;8(14):22800-22810. doi: 10.18632/oncotarget.15205.
2
A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.新型抗癌药物淫羊藿素通过IL-6/Jak2/Stat3信号通路抑制肝癌起始和恶性生长。
Oncotarget. 2015 Oct 13;6(31):31927-43. doi: 10.18632/oncotarget.5578.
3
Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma.茵陈色原酮通过下调肝癌中 AFP 基因的表达促进肝癌细胞凋亡并抑制其增殖。
BMC Cancer. 2021 Mar 25;21(1):318. doi: 10.1186/s12885-021-08043-9.
4
Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent.脂质体C8神经酰胺作为一种有效的抗肝细胞癌药物的临床前评价
PLoS One. 2016 Jan 4;11(1):e0145195. doi: 10.1371/journal.pone.0145195. eCollection 2016.
5
The blockage of Ras/ERK pathway augments the sensitivity of SphK1 inhibitor SKI II in human hepatoma HepG2 cells.Ras/ERK 通路的阻断增强了 SphK1 抑制剂 SKI II 在人肝癌 HepG2 细胞中的敏感性。
Biochem Biophys Res Commun. 2013 Apr 26;434(1):35-41. doi: 10.1016/j.bbrc.2013.03.070. Epub 2013 Mar 29.
6
SPHK1 inhibitor suppresses cell proliferation and invasion associated with the inhibition of NF-κB pathway in hepatocellular carcinoma.鞘氨醇激酶1抑制剂通过抑制核因子κB通路抑制肝癌细胞的增殖和侵袭。
Tumour Biol. 2015 Mar;36(3):1503-9. doi: 10.1007/s13277-014-2665-7. Epub 2014 Dec 24.
7
The impact of sphingosine kinase 1 on the prognosis of hepatocellular carcinoma patients with portal vein tumor thrombus.鞘氨醇激酶1对伴有门静脉癌栓的肝细胞癌患者预后的影响
Ann Hepatol. 2015 Mar-Apr;14(2):198-206.
8
Ceramide production mediates cinobufotalin-induced growth inhibition and apoptosis in cultured hepatocellular carcinoma cells.神经酰胺生成介导华蟾酥毒基诱导培养的肝癌细胞生长抑制和凋亡。
Tumour Biol. 2015 Aug;36(8):5763-71. doi: 10.1007/s13277-015-3245-1. Epub 2015 Feb 28.
9
Hepatitis B virus X protein promotes human hepatoma cell growth via upregulation of transcription factor AP2α and sphingosine kinase 1.乙型肝炎病毒X蛋白通过上调转录因子AP2α和鞘氨醇激酶1促进人肝癌细胞生长。
Acta Pharmacol Sin. 2015 Oct;36(10):1228-36. doi: 10.1038/aps.2015.38. Epub 2015 Jun 15.
10
The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.新型mTOR激酶抑制剂CZ415的抗肝癌细胞活性
Biochem Biophys Res Commun. 2017 Jun 3;487(3):494-499. doi: 10.1016/j.bbrc.2017.03.156. Epub 2017 Mar 30.

引用本文的文献

1
Biomimetic nanoparticles for targeted therapy of liver disease.用于肝病靶向治疗的仿生纳米颗粒。
RSC Pharm. 2025 Apr 28. doi: 10.1039/d5pm00044k.
2
Small-molecule-based targeted therapy in liver cancer.基于小分子的肝癌靶向治疗。
Mol Ther. 2024 Oct 2;32(10):3260-3287. doi: 10.1016/j.ymthe.2024.08.001. Epub 2024 Aug 8.
3
Hyaluronic acid-modified liposomes Potentiated anti-hepatocellular carcinoma of icaritin.透明质酸修饰的脂质体增强了淫羊藿素的抗肝癌作用。

本文引用的文献

1
Aqueous Oldenlandia diffusa extracts inhibits colorectal cancer cells via activating AMP-activated protein kinase signalings.白花蛇舌草水提取物通过激活AMP活化蛋白激酶信号通路抑制结肠癌细胞。
Oncotarget. 2016 Jul 19;7(29):45889-45900. doi: 10.18632/oncotarget.9969.
2
KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms.KU-0060648 通过依赖 DNA-PKcs 和不依赖 DNA-PKcs 的机制抑制肝癌细胞。
Oncotarget. 2016 Mar 29;7(13):17047-59. doi: 10.18632/oncotarget.7742.
3
Icaritin activates JNK-dependent mPTP necrosis pathway in colorectal cancer cells.
Front Pharmacol. 2024 Jul 11;15:1437515. doi: 10.3389/fphar.2024.1437515. eCollection 2024.
4
Integrative roles of sphingosine kinase in liver pathophysiology.鞘氨醇激酶在肝脏病理生理学中的综合作用
Toxicol Res. 2023 Jun 19;39(4):549-564. doi: 10.1007/s43188-023-00193-1. eCollection 2023 Oct.
5
Targeting SphK1/2 by SKI-178 inhibits prostate cancer cell growth.靶向 SphK1/2 抑制前列腺癌细胞生长。
Cell Death Dis. 2023 Aug 21;14(8):537. doi: 10.1038/s41419-023-06023-4.
6
Identification of G protein subunit alpha i2 as a promising therapeutic target of hepatocellular carcinoma.鉴定 G 蛋白亚单位 αi2 为肝细胞癌有希望的治疗靶点。
Cell Death Dis. 2023 Feb 20;14(2):143. doi: 10.1038/s41419-023-05675-6.
7
Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges.用于原发性肝癌治疗的中草药:前景与挑战
Front Pharmacol. 2022 May 5;13:889799. doi: 10.3389/fphar.2022.889799. eCollection 2022.
8
Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy.在癌症治疗药物研发中靶向鞘氨醇激酶/1-磷酸鞘氨醇信号轴
Cancers (Basel). 2021 Apr 15;13(8):1898. doi: 10.3390/cancers13081898.
9
Icaritin inhibits PD-L1 expression by Targeting Protein IκB Kinase α.伊卡替丁通过靶向蛋白 IκB 激酶 α 抑制 PD-L1 的表达。
Eur J Immunol. 2021 Apr;51(4):978-988. doi: 10.1002/eji.202048905. Epub 2021 Feb 9.
10
The Tumorigenic Effect of Sphingosine Kinase 1 and Its Potential Therapeutic Target.鞘氨醇激酶 1 的致瘤作用及其潜在的治疗靶点。
Cancer Control. 2020 Jan-Dec;27(1):1073274820976664. doi: 10.1177/1073274820976664.
淫羊藿素激活结肠癌细胞中JNK依赖的线粒体通透性转换孔坏死途径。
Tumour Biol. 2016 Mar;37(3):3135-44. doi: 10.1007/s13277-015-4134-3. Epub 2015 Oct 1.
4
A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.新型抗癌药物淫羊藿素通过IL-6/Jak2/Stat3信号通路抑制肝癌起始和恶性生长。
Oncotarget. 2015 Oct 13;6(31):31927-43. doi: 10.18632/oncotarget.5578.
5
C6 ceramide dramatically increases vincristine sensitivity both in vivo and in vitro, involving AMP-activated protein kinase-p53 signaling.C6 神经酰胺在体内和体外均显著提高长春新碱敏感性,涉及 AMP 激活的蛋白激酶 - p53 信号通路。
Carcinogenesis. 2015 Sep;36(9):1061-70. doi: 10.1093/carcin/bgv094. Epub 2015 Jun 25.
6
MicroRNA-101 down-regulates sphingosine kinase 1 in colorectal cancer cells.微小RNA-101下调结肠癌细胞中的鞘氨醇激酶1
Biochem Biophys Res Commun. 2015 Aug 7;463(4):954-60. doi: 10.1016/j.bbrc.2015.06.041. Epub 2015 Jun 9.
7
SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo.鞘氨醇激酶1抑制剂II(SKI-II)在体外和体内均能抑制急性髓性白血病细胞的生长。
Biochem Biophys Res Commun. 2015 May 15;460(4):903-8. doi: 10.1016/j.bbrc.2015.03.114. Epub 2015 Mar 28.
8
The impact of sphingosine kinase 1 on the prognosis of hepatocellular carcinoma patients with portal vein tumor thrombus.鞘氨醇激酶1对伴有门静脉癌栓的肝细胞癌患者预后的影响
Ann Hepatol. 2015 Mar-Apr;14(2):198-206.
9
Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii.淫羊藿主要生物活性成分淫羊藿苷的药理作用及药代动力学特性
Life Sci. 2015 Apr 1;126:57-68. doi: 10.1016/j.lfs.2015.01.006. Epub 2015 Jan 26.
10
SPHK1 inhibitor suppresses cell proliferation and invasion associated with the inhibition of NF-κB pathway in hepatocellular carcinoma.鞘氨醇激酶1抑制剂通过抑制核因子κB通路抑制肝癌细胞的增殖和侵袭。
Tumour Biol. 2015 Mar;36(3):1503-9. doi: 10.1007/s13277-014-2665-7. Epub 2014 Dec 24.